WallStSmart

Bioceres Crop Solutions Corp (BIOX)vsCorteva Inc (CTVA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Corteva Inc generates 6910% more annual revenue ($17.89B vs $255.21M). CTVA leads profitability with a 6.5% profit margin vs -96.9%. CTVA appears more attractively valued with a PEG of 1.31. CTVA earns a higher WallStSmart Score of 64/100 (C+).

BIOX

Hold

46

out of 100

Grade: D+

Growth: 5.3Profit: 2.0Value: 4.7Quality: 2.5
Piotroski: 3/9Altman Z: 0.63

CTVA

Buy

64

out of 100

Grade: C+

Growth: 4.7Profit: 5.5Value: 4.0Quality: 6.0
Piotroski: 4/9Altman Z: 1.49
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BIOX.

CTVASignificantly Overvalued (-68.0%)

Margin of Safety

-68.0%

Fair Value

$44.32

Current Price

$77.46

$33.14 premium

UndervaluedFair: $44.32Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BIOX2 strengths · Avg: 9.0/10
Price/BookValuation
0.4x10/10

Reasonable price relative to book value

EPS GrowthGrowth
34.4%8/10

Earnings expanding 34.4% YoY

CTVA4 strengths · Avg: 8.5/10
Market CapQuality
$51.88B9/10

Large-cap with strong market position

Debt/EquityHealth
0.149/10

Conservative balance sheet, low leverage

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Operating MarginProfitability
23.7%8/10

Strong operational efficiency at 23.7%

Areas to Watch

BIOX4 concerns · Avg: 3.0/10
PEG RatioValuation
1.954/10

Expensive relative to growth rate

Market CapQuality
$31.30M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-359.8%2/10

ROE of -359.8% — below average capital efficiency

CTVA4 concerns · Avg: 2.5/10
Return on EquityProfitability
4.8%3/10

ROE of 4.8% — below average capital efficiency

Profit MarginProfitability
6.5%3/10

6.5% margin — thin

P/E RatioValuation
41.9x2/10

Premium valuation, high expectations priced in

Free Cash FlowQuality
$-2.97B2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : BIOX

The strongest argument for BIOX centers on Price/Book, EPS Growth.

Bull Case : CTVA

The strongest argument for CTVA centers on Market Cap, Debt/Equity, Price/Book. Revenue growth of 11.0% demonstrates continued momentum. PEG of 1.31 suggests the stock is reasonably priced for its growth.

Bear Case : BIOX

The primary concerns for BIOX are PEG Ratio, Market Cap, Piotroski F-Score. Debt-to-equity of 3.55 is elevated, increasing financial risk.

Bear Case : CTVA

The primary concerns for CTVA are Return on Equity, Profit Margin, P/E Ratio. A P/E of 41.9x leaves little room for execution misses.

Key Dynamics to Monitor

BIOX profiles as a turnaround stock while CTVA is a value play — different risk/reward profiles.

CTVA carries more volatility with a beta of 0.59 — expect wider price swings.

CTVA is growing revenue faster at 11.0% — sustainability is the question.

Monitor AGRICULTURAL INPUTS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

CTVA scores higher overall (64/100 vs 46/100) and 11.0% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Bioceres Crop Solutions Corp

BASIC MATERIALS · AGRICULTURAL INPUTS · USA

Bioceres Crop Solutions Corp.

Corteva Inc

BASIC MATERIALS · AGRICULTURAL INPUTS · USA

Corteva, Inc. (also known as Corteva Agriscience) is a major American agricultural chemical and seed company that was the agricultural unit of DowDuPont prior to being spun off as an independent public company.

Visit Website →

Want to dig deeper into these stocks?